Oncolytics Biotech (ONCY) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Spero Therapeutics (SPRO) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 50.2% versus a loss of 57.8%. Over five years, ONCY leads with a -77.8% price change compared with -93.5% for SPRO. Oncolytics Biotech is the larger company by market cap ($65.3 million vs $64.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCY | SPRO |
|---|---|---|
| Share price | $0.4981 | $1.10 |
| Market cap | $65.31M | $64.06M |
| 1-day change | -9.04% | -2.65% |
| YTD return | -42.75% | -52.79% |
| 1-year return | -57.79% | -50.23% |
| 5-year return | -77.76% | -93.48% |
| P/E ratio (TTM) | — | 7.86 |
| EPS (TTM) | $-0.35 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $66.80M |
| Revenue growth (YoY) | — | +39.24% |
| Net income (latest FY) | $-28.76M | $8.57M |
| Operating margin | — | 9.45% |
| Net margin | — | 12.83% |
| 52-week high | $1.32 | $3.08 |
| 52-week low | $0.44 | $1.08 |
| Distance from 52-week high | -62.27% | -64.29% |
| Analyst consensus | buy | none |
| Avg. price target upside | +733.17% | +354.55% |
| Average volume | 1.09M | 962.41K |
| Shares outstanding | 131.12M | 58.23M |
| Employees | 29 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
ONCY vs SPRO FAQ
Which is bigger, Oncolytics Biotech or Spero Therapeutics?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $65.31M compared with $64.06M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, ONCY or SPRO?
SPRO returned -50.23% over the past 12 months, compared with -57.79% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Oncolytics Biotech and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.